The fresh funding will help the biotech startup advance a candidate to treat a genetic disorder, “ATTR-CM,” that has become a ...

The prominent investor aims to merge its latest special purpose acquisition company with a Chinese biotech, according to a ...

Xpovio combined with Incyte’s Jakafi helped on one key measure but missed on other goal in a disorder that, by one analyst’s ...

Acquiring Ouro Medicines, which launched last year, hands Gilead an antibody designed to bind to BCMA and CD3, a pair of immune cell proteins that are popular targets for drugmakers.

Cohen says he looked at around two dozen companies since Acorda wound down. Oryon Cell Therapies, with its funding, data and ...

Company shares climbed by more than 20% on Phase 2 study results suggesting the therapy could provide sustained relief when ...

The partners said the shot produced “clinically meaningful” efficacy despite missing its main study objective, a finding they ...

Industry executives can share their views on the “national priority” program at a June meeting. Elsewhere, Sanofi licensed a ...

The hefty funding will support a U.S. and China-based startup that’s amassed a pipeline of nearly 20 drugs and formed two ...

In a letter to European patients, Roche said its decision to end development of “emugrobart” was based on the drug “not ...

Acquiring a unit of privately held Synnovation Therapeutics hands Novartis a prospect that might improve on medicines that, ...

Imcivree’s approval in a type of obesity driven by brain injury could unlock an opportunity Wall Street analysts believe to ...